Smitha Kota

TL;DR: High-throughput screening of a library of small molecules combined with a structure-activity relationship approach resulted in the identification of FRAX597, a small-molecule pyridopyrimidinone, as a potent inhibitor of the group I PAKs, identifying a novel class of orally available ATP-competitive Group IPAK inhibitors with significant potential for the treatment of NF2 and other cancers.

TL;DR: Findings implicate Notch1 as a critical effector in Kras-driven lung adenocarcinoma and as a regulator of p53 at a posttranslational level and provides new insights to explain the correlation between Notch 1 activity and poor prognosis in patients with NSCLC carrying wild-type p53.

TL;DR: The use of TR-FRET screening is reported to successfully identify a novel capsid inhibitor, ebselen, validating HIV-1 capsid as a promising target for drug development.

TL;DR: It is found that YAP function is required for NF2-null Schwann cell survival, proliferation, and tumor growth in vivo and treatment with the COX-2 inhibitor celecoxib significantly inhibited the growth ofNF2- null Schwann cells and tumor Growth in a mouse model of NF2.

TL;DR: The essential role of core as a key organizer of HCV particle assembly is underline, the importance of oligomerization is confirmed, the interaction with viral helicase is revealed, and a new molecular understanding of the formation of the viral particle at the level of the lipid droplets is supported, before its migration to the site of release and budding.